Allergy Therapeutics (LON:AGY) Hits New 12-Month High - Time to Buy?

Key Points

• Allergy Therapeutics' stock reached a new 52-week high of GBX 8.50 ($0.11), trading up 6.3% on strong volume, with a market cap of £417.78 million.
• The company focuses on the treatment and diagnosis of allergic disorders with products including aluminium-free immunotherapy vaccines available across nine major European countries.
• Allergy Therapeutics has a negative P/E ratio of -8.19, indicating current losses, and a high debt-to-equity ratio of 835.48, suggesting potential financial risk.

Allergy Therapeutics plc (LON:AGY - )'s stock price reached a new 52-week high on Monday . The company traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11), with a volume of 139351 shares changing hands. The stock had previously closed at GBX 8 ($0.11).

Allergy Therapeutics Trading Up 6.3%

The company has a market cap of £417.78 million, a price-to-earnings ratio of -8.19, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. The firm's 50-day moving average price is GBX 7.48 and its 200 day moving average price is GBX 6.89.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.